Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Kerry A. Rogers, MD, Amy M. Lehman, MAS, Carolyn Cheney, BS, Virginia M. Goettl, DVM , PhD, Rose Mantel, Lisa L. Smith, MS, Minh Tran, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 1259.

https://doi.org/10.1182/blood.V128.22.1259.1259

Published: 2016

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Sean D. Reiff, Rose Mantel, Lisa L. Smith, MS, Samantha McWhorter, Virginia M. Goettl, DVM , PhD, Amy J. Johnson, PhD, Sudharsan Eathiraj, Giovanni Abbadessa, MD, Brian Schwartz, MD, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2016) 128 (22): 3232.

https://doi.org/10.1182/blood.V128.22.3232.3232

Published: 2016

Journal Articles

Exploring the Role of the Recurrent Exportin 1 (XPO1/CRM1) Mutations E571G and E571K in Chronic Lymphocytic Leukemia

Zachary A. Hing, BS, James S. Blachly, MD, Virginia M. Goettl, DVM, PhD, Guramrit Singh, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2016) 128 (22): 972.

https://doi.org/10.1182/blood.V128.22.972.972

Published: 2016

Journal Articles

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

Nicole R. Grieselhuber, MD PhD, Shaneice R. Mitchell, BS, Shelley Orwick, BS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Sumithra Vasu, MBBS, William Blum, MD, James S. Blachly, MD, David M. Lucas, PhD, Ramiro Garzon, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3941.

https://doi.org/10.1182/blood.V128.22.3941.3941

Published: 2016

Journal Articles

NFkB p50 ( Nfkb1 ) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

Erin K Hertlein, PhD, Timothy L Chen, David M Lucas, PhD, Nikhil Gupta, Jessica MacMurray, Virginia M. Goettl, DVM , PhD, Amy M. Lehman, MAS, Amy J. Johnson, PhD, John C Byrd, MD

Blood (2015) 126 (23): 1248.

https://doi.org/10.1182/blood.V126.23.1248.1248

Published: 2015

Journal Articles

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

Blood (2015) 126 (23): 317.

https://doi.org/10.1182/blood.V126.23.317.317

Published: 2015

Journal Articles

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

Dalia El-Gamal, PhD, Zachary A. Hing, BS, Shaneice Mitchell, BS, Taylor D. LaFollette, Paul J. Brennan, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD MPH, Farrukh Awan, MD MS, Leslie A. Andritsos, MD, James S. Blachly, MD, Katie Williams, MS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Jennifer A. Woyach, MD, Amy M. Lehman, MAS, Lianbo Yu, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2015) 126 (23): 318.

https://doi.org/10.1182/blood.V126.23.318.318

Published: 2015

Journal Articles

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

Shaneice Mitchell, BS, Shelley Orwick, BS, Matthew Cannon, BS, Virginia M. Goettl, DVM , PhD, Taylor D. LaFollette, Erkan Baloglu, PhD, William Senapedis, PhD, Alison R. Walker, MD, Bhavana Bhatnagar, Alice S. Mims, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, William Blum, MD, David M. Lucas, PhD, James S. Blachly, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2015) 126 (23): 2471.

https://doi.org/10.1182/blood.V126.23.2471.2471

Published: 2015

Journal Articles

Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia (CLL).

Michael D. De Lay, Amy J. Johnson, PhD, David M. Lucas, PhD, Darius T. Durr, Ellen M. Sass, Virginia M. Goettl, DVM, PhD, Amy Lehman, David Jarjoura, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2007) 110 (11): 3095.

https://doi.org/10.1182/blood.V110.11.3095.3095

Published: 2007

NARROW

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Exploring the Role of the Recurrent Exportin 1 (XPO1/CRM1) Mutations E571G and E571K in Chronic Lymphocytic Leukemia

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

NFkB p50 ( Nfkb1 ) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia

Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and I n Vi tro Potency in B-Cell Malignancies

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only